Explore the words cloud of the RESPINE project. It provides you a very rough idea of what is the project "RESPINE" about.
The following table provides information about the project.
CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER
|Coordinator Country||France [FR]|
|Total cost||5˙555˙836 €|
|EC max contribution||5˙555˙836 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-01-01 to 2020-12-31|
Take a look of project's partnership.
|1||CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER||FR (MONTPELLIER)||coordinator||837˙963.00|
|2||CITOSPIN S.L.||ES (VALLADOLID)||participant||964˙126.00|
|3||ASSISTANCE PUBLIQUE HOPITAUX DE PARIS||FR (PARIS)||participant||495˙750.00|
|4||UNIVERSIDAD DE VALLADOLID||ES (VALLADOLID)||participant||402˙537.00|
|5||CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES||FR (NANTES)||participant||375˙125.00|
|6||UNIVERSIDAD DE NAVARRA||ES (PAMPLONA)||participant||363˙000.00|
|7||UNIVERSITA CAMPUS BIO MEDICO DI ROMA||IT (ROMA)||participant||321˙362.00|
|8||INSTITUT DE TERAPIA REGENERATIVA TISULAR SL||ES (BARCELONA)||participant||300˙860.00|
|9||BG KLINIKUM BERGMANNSTROST HALLE GGMBH||DE (HALLE)||participant||260˙012.00|
|10||NATIONAL UNIVERSITY OF IRELAND GALWAY||IE (Galway)||participant||258˙745.00|
|11||UNIVERSITE DE MONTPELLIER||FR (MONTPELLIER)||participant||249˙500.00|
|12||UNIVERCELL BIOSOLUTIONS SAS||FR (TOULOUSE)||participant||233˙716.00|
|13||CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS||FR (PARIS)||participant||220˙306.00|
|14||ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK||FR (PARIS)||participant||177˙150.00|
|15||CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES||FR (RENNES CEDEX 9)||participant||95˙679.00|
The World Health Organisation (WHO) has included low back pain in its list of twelve priority diseases. Notably, Degenerative disc disease (DDD) presents a large, unmet medical need which results in a disabling loss of mechanical function. Today, no efficient therapy is available. Chronic cases often receive surgery, which may lead to biomechanical problems and accelerated degeneration of adjacent segments. Our consortium partners have developed and studied stem cell-based, regenerative therapies with encouraging results in phase 1 and 2a trials. Patients exhibited rapid and progressive improvement of functional and pain indexes by 50% within 6 months and by 65% to 78% after 1 year with no side effects. In addition, MRI T2 relaxation measurements demonstrated a significant improvement. To develop the world’s first rigorously proven, effective treatment of DDD, RESPINE aims to assess, via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. This innovative therapy aims to rapidly (within 3 months) and sustainably (at least 24 months) reduce pain and disability. In addition, the consortium aims to provide new knowledge on immune response & safety associated with allogeneic BM-MSC intradiscal injection. This simple procedure would be cost-effective, minimally invasive, and standardised. The transfer to the clinic will be prepared at a cost below 10k€ thanks to the strategy of production of allogenic cells, automation & EU standardisation. At the end of the RESPINE trial, we aim to propose a broadly available and clinically applicable treatment for DDD, marketed by European SMEs.
|Dissemination and Communication||Documents, reports||2020-03-23 11:32:02|
|Registration of clinical trial on EudraCT and Clinicaltrials.gov||Documents, reports||2020-03-23 11:32:02|
Take a look to the deliverables list in detail: detailed list of RESPINE deliverables.
|year||authors and title||journal||last update|
Abbie. L. A. Binch, Stephen M. Richardson, Judith A. Hoyland, Frank P. Barry
Combinatorial conditioning of adipose derivedâ€mesenchymal stem cells enhances their neurovascular potential: Implications for intervertebral disc degeneration
published pages: , ISSN: 2572-1143, DOI: 10.1002/jsp2.1072
|JOR SPINE 2/4||2020-03-23|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESPINE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RESPINE" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More